United Services Automobile Association Invests $340,000 in TG Therapeutics, Inc. $TGTX

Key Points

• United Services Automobile Association acquired a new stake in TG Therapeutics, purchasing 8,531 shares valued at approximately $340,000.
• Goldman Sachs upgraded TG Therapeutics to a "hold" rating with a target price of $37.00, contributing to an average rating of "Moderate Buy" for the stock.
• In its latest earnings report, TG Therapeutics reported $0.17 EPS, missing estimates, but showed a 92.1% revenue increase compared to the same quarter last year.

United Services Automobile Association acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,531 shares of the biopharmaceutical company's stock, valued at approximately $340,000.

Several other hedge funds have also recently modified their holdings of the stock. Soleus Capital Management L.P. increased its holdings in shares of TG Therapeutics by 5.8% during the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company's stock valued at $80,705,000 after acquiring an additional 146,702 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of TG Therapeutics by 21.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company's stock valued at $75,683,000 after acquiring an additional 345,059 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of TG Therapeutics by 1,809.9% during the first quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company's stock valued at $47,830,000 after acquiring an additional 1,149,526 shares in the last quarter. Invesco Ltd. increased its holdings in shares of TG Therapeutics by 30.2% during the first quarter. Invesco Ltd. now owns 1,210,842 shares of the biopharmaceutical company's stock valued at $47,744,000 after acquiring an additional 281,099 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of TG Therapeutics by 1.3% during the first quarter. Principal Financial Group Inc. now owns 841,011 shares of the biopharmaceutical company's stock valued at $33,161,000 after acquiring an additional 10,827 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

Insider Activity

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the firm's stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the sale, the director directly owned 94,061 shares of the company's stock, valued at $3,032,526.64. This trade represents a 18.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.64% of the stock is owned by company insiders.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upgraded shares of TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a report on Thursday, July 10th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $46.25.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX traded down $0.30 during midday trading on Friday, reaching $32.16. 2,386,153 shares of the company's stock traded hands, compared to its average volume of 1,982,735. TG Therapeutics, Inc. has a 1 year low of $21.16 and a 1 year high of $46.48. The company has a market cap of $5.10 billion, a P/E ratio of 86.92 and a beta of 1.88. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The company has a fifty day simple moving average of $32.38 and a two-hundred day simple moving average of $35.72.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The business had revenue of $141.15 million for the quarter, compared to analysts' expectations of $147.76 million. During the same quarter last year, the business earned $0.04 EPS. The company's quarterly revenue was up 92.1% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS. Equities analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.